Declaration of Competing Interest statements were not included in the published version of the following articles that appeared in previous issues of Clinical and Translational Radiation Oncology.
The appropriate Declaration/Competing Interest statements, provided by the Authors, are included below.
-
1.
“Isodose 20 Gy found as a threshold dose for radiation recall dermatitis” [Clinical and Translational Radiation Oncology, 2019; 17C: 14-16/148] 10.1016/j.ctro.2019.03.003
Declaration of competing interest: No conflict of interest
-
2.
“Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma” [Clinical and Translational Radiation Oncology, 2018; 9C: 30-34/76] 10.1016/j.ctro.2018.01.002
Declaration of competing interest: No conflict of interest
-
3.
“Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: a phase I/II study (DUCRO)” [Clinical and Translational Radiation Oncology, 2018; 9C: 32-47/79] 10.1016/j.ctro.2018.01.005
Declaration of competing interest: No conflict of interest
-
4.
“Relative biological effectiveness in proton beam therapy – current knowledge and future challenges” [Clinical and Translational Radiation Oncology, 2018; 9C: 35-41/80] 10.1016/j.ctro.2018.01.006
Declaration of competing interest: No conflict of interest
-
5.
“Salvage radiotherapy after radical prostatectomy: long-term results of urinary incontinence, toxicity and treatment outcomes” [Clinical and Translational Radiation Oncology, 2018;11C: 26-32/94] 10.1016/j.ctro.2018.05.001
Declaration of competing interest: No conflict of interest
-
6.
“Single dose partial breast irradiation using an MRI linear accelerator in the supine and prone treatment position” [Clinical and Translational Radiation Oncology, 2019; 14C: 1-7/107] 10.1016/j.ctro.2018.09.001
Declaration of competing interest: Dr Charaghvandi reports personal fees from Pink Ribbon association, during the conduct of the study.
-
7.
“Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL Stage 2a-2b/ Bayesian Phase II Trial” [Clinical and Translational Radiation Oncology, 2018; 13C: 19-23/105] 10.1016/j.ctro.2018.08.003
Declaration of competing interest: “This research is supported by the Andrew Sabin Family Foundation; Dr. Fuller is a Sabin Family Foundation Fellow. Dr. Fuller receives funding and salary support from the National Institutes of Health (NIH), including: the National Institute for Dental and Craniofacial Research Award (1R01DE025248-01/R56DE025248-01); a National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/NSF Initiative on Quantitative Approaches to Biomedical Big Data (QuBBD) Grant (NSF 1557679); the NIH Big Data to Knowledge (BD2K) Program of the National Cancer Institute (NCI) Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Award (1R01CA214825-01); NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148-01); an NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672) and an NIH/NCI Head and Neck Specialized Programs of Research Excellence (SPORE) Developmental Research Program Award (P50 CA097007-10). Dr. Fuller has received direct industry grant support and travel funding from Elekta AB.”
-
8.
“Dose to penile bulb is not associated with erectile dysfunction 18 months post radiotherapy: a secondary analysis of a randomized trial” [Clinical and Translational Radiation Oncology, 2018;13C: 50-56/112] 10.1016/j.ctro.2018.09.006
Declaration of competing interest: No conflict of interest
-
9.
“An In-Silico Quality Assurance Study of Contouring Target Volumes in Thoracic Tumors within a Cooperative Group Setting” [Clinical and Translational Radiation Oncology, 2019; 15C: 83-92/133] 10.1016/j.ctro.2019.01.001
Declaration of competing interest: No conflict of interest
-
10.
“Rectal volume variations and estimated rectal dose during 8 weeks of image-guided radical 3D conformal external beam radiotherapy for prostate cancer.” [Clinical and Translational Radiation Oncology, 2019; 15C: 113-117/142] 10.1016/j.ctro.2019.02.003
Declaration of competing interest: No conflict of interest
-
11.
“Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy” [Clinical and Translational Radiation Oncology, 2019; 17C: 17-23/167] 10.1016/j.ctro.2019.04.016
Declaration of competing interest: No conflict of interest
-
12.
“Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy” [Clinical and Translational Radiation Oncology, 2020; 22C: 15-21/231] 10.1016/j.ctro.2020.02.005
Declaration of competing interest: No conflict of interest
-
13.
“4D-MRI Driven MR-guided Online Adaptive Radiotherapy for Abdominal Stereotactic Body Radiation Therapy on a High Field MR-Linac: Implementation and Initial Clinical Experience” [Clinical and Translational Radiation Oncology, 2020; 23C: 72-79/257] 10.1016/j.ctro.2020.05.002
Declaration of competing interest: Research support from Elekta Instruments AB
-
14.
“Machine Learning Highlights the Deficiency of Conventional Dosimetric Constraints for Prevention of High-Grade Radiation Esophagitis in Non-Small Cell Lung Cancer Treated with Chemoradiation” [Clinical and Translational Radiation Oncology, 2020; 22C: 69-75/240] 10.1016/j.ctro.2020.03.007
Declaration of competing interest: Dr. Luna Castaneda reports grants from Emerson Collective, during the conduct of the study; In addition, Dr. Luna Castaneda has a patent Systems and Methods for Generating Improved Decision Trees pending.
-
15.
“Impact of suboptimal dosimetric coverage of pretherapeutic 18F-FDG PET/CT hotspots on outcome in patients with locally advanced cervical cancer treated with chemoradiotherapy followed by brachytherapy” [Clinical and Translational Radiation Oncology, 2020; 23C: 50-59/259] 10.1016/j.ctro.2020.05.004
Declaration of competing interest: No conflict of interest